Interleukin 6: from bench to bedside

被引：510

作者：

Nishimoto, Norihiro ^{[1
]}

Kishimoto, Tadamitsu ^{[1
]}

机构：

[1] Osaka Univ, Grad Sch Frontier Biosci, Lab Immune regulat, Osaka 5650871, Japan

来源：

NATURE CLINICAL PRACTICE RHEUMATOLOGY | 2006年 / 2卷 / 11期

关键词：

interleukin; 6; rheumatoid arthritis; systemic juvenile idiopathic arthritis; therapy; tocilizumab;

D O I：

10.1038/ncprheum0338

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

Interleukin (IL)-6 is a pleiotropic cytokine that has important roles in the regulation of the immune response, inflammation, and hematopoiesis. Disruption of IL-6 regulation might, however, affect the immune response and consequently induce immune-mediated inflammatory diseases such as rheumatoid arthritis, systemic juvenile idiopathic arthritis, Castleman disease, and Crohn's disease. Overproduction of IL-6 also contributes, through its roles as a growth factor or an antiapoptotic factor, to the development of malignant diseases such as multiple myeloma and renal cancer. Progress in the study of IL-6 has increased our understanding of the pathological roles of this cytokine in these diseases and provided key evidence that antagonizing its activities can be used as a therapeutic strategy. The application of molecular biology techniques to design monoclonal antibodies as therapeutic agents has made it possible to regulate the IL-6 signal to successfully treat diseases that have so far proved refractory to conventional therapies. Blocking IL-6 actions by use of a humanized antibody, tocilizumab, which targets the IL-6 receptor, has been proven to be therapeutically effective for rheumatoid arthritis, systemic juvenile idiopathic arthritis, Castleman disease and Crohn's disease. In this review, we discuss a paradigm of IL-6 from basic science to clinical use.

引用

页码：619 / 626

页数：8

共 60 条

[1]

Interleukin 6 is required for the development of collagen-induced arthritis [J].

Alonzi, T ;

Fattori, E ;

Lazzaro, D ;

Costa, P ;

Probert, L ;

Kollias, G ;

De Benedetti, F ;

Poli, V ;

Ciliberto, G .

JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (04) :461-468

[2]

Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation:: Evidence in Crohn disease and experimental colitis in vivo [J].

Atreya, R ;

Mudter, J ;

Finotto, S ;

Müllberg, J ;

Jostock, T ;

Wirtz, S ;

Schütz, M ;

Bartsch, B ;

Holtmann, M ;

Becker, C ;

Strand, D ;

Czaja, J ;

Schlaak, JF ;

Lehr, HA ;

Autschbach, F ;

Schürmann, G ;

Nishimoto, N ;

Yoshizaki, K ;

Ito, H ;

Kishimoto, T ;

Galle, PR ;

Rose-John, S ;

Neurath, MF .

NATURE MEDICINE, 2000, 6 (05) :583-588

[3]

A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis [J].

Atsumi, T ;

Ishihara, K ;

Kamimura, D ;

Ikushima, H ;

Ohtani, T ;

Hirota, S ;

Kobayashi, H ;

Park, SJ ;

Saeki, Y ;

Kitamura, Y ;

Hirano, T .

JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 196 (07) :979-990

[4]

Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis [J].

Cazzola, M ;

Ponchio, L ;

deBenedetti, F ;

Ravelli, A ;

Rosti, V ;

Beguin, Y ;

Invernizzi, R ;

Barosi, G ;

Martini, A .

BLOOD, 1996, 87 (11) :4824-4830

[5]

Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis - A randomized, double-blind, placebo-controlled, dose-escalation trial [J].

Choy, EHS ;

Isenberg, DA ;

Garrood, T ;

Farrow, S ;

Ioannou, Y ;

Bird, H ;

Cheung, N ;

Williams, B ;

Hazleman, B ;

Price, R ;

Yoshizaki, K ;

Nishimoto, N ;

Kishimoto, T ;

Panayi, GS .

ARTHRITIS AND RHEUMATISM, 2002, 46 (12) :3143-3150

[6]

De Benedetti F, 1998, J RHEUMATOL, V25, P203

[7]

AMERICAN-COLLEGE-OF-RHEUMATOLOGY PRELIMINARY DEFINITION OF IMPROVEMENT IN RHEUMATOID-ARTHRITIS [J].

FELSON, DT ;

ANDERSON, JJ ;

BOERS, M ;

BOMBARDIER, C ;

FURST, D ;

GOLDSMITH, C ;

KATZ, LM ;

LIGHTFOOT, R ;

PAULUS, H ;

STRAND, V ;

TUGWELL, P ;

WEINBLATT, M ;

WILLIAMS, HJ ;

WOLFE, F ;

KIESZAK, S .

ARTHRITIS AND RHEUMATISM, 1995, 38 (06) :727-735

[8]

The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis [J].

Fishman, D ;

Faulds, G ;

Jeffery, R ;

Mohamed-Ali, V ;

Yudkin, JS ;

Humphries, S ;

Woo, P .

JOURNAL OF CLINICAL INVESTIGATION, 1998, 102 (07) :1369-1376

[9]

Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein [J].

Gillmore, JD ;

Lovat, LB ;

Persey, MR ;

Pepys, MB ;

Hawkins, PN .

LANCET, 2001, 358 (9275) :24-29

[10]

Distinct contribution of IL-6, TNF-α, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice [J].

Hata, H ;

Sakaguchi, N ;

Yoshitomi, H ;

Iwakura, Y ;

Sekikawa, K ;

Azuma, Y ;

Kanai, C ;

Moriizumi, E ;

Nomura, T ;

Nakamura, T ;

Sakaguchi, S .

JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (04) :582-588

← 1 2 3 4 5 6 →